ASX 200 healthcare stock tumbles amid $200 million US acquisition

The ASX 200 healthcare company is acquiring a US medical technology business.

| More on:
Health professional looking at a laptop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

S&P/ASX 200 Index (ASX: XJO) healthcare stock Sonic Healthcare Ltd (ASX: SHL) is taking a tumble today.

Shares in the global pathology provider closed yesterday trading for $30.50. At the time of writing on Thursday, shares are swapping hands for $29.09 apiece, down 4.6%.

That sees the healthcare share underperforming the ASX 200 today, with the benchmark index down 0.5% at this same time.

This comes following news of a United States-based medical acquisition.

What medical asset is the ASX 200 healthcare stock acquiring?

The Sonic Healthcare share price is dipping after the ASX 200 healthcare stock reported that it has signed binding agreements to acquire Pathology Watch.

Located in the US state of Utah, the medical technology business has developed and commercialised an integrated, end-to-end digital pathology platform for skin pathology.

Sonic will pay US$130 million (AU$200 million) for business, which it will fund from existing cash and debt facilities. Management said it does not consider the transaction to be material for Sonic Healthcare.

Management noted that Pathology Watch is currently at pre-profit stage. However, they expect to "achieve attractive earnings per share and return on invested capital accretion" over the coming years.

The ASX 200 healthcare stock said the opportunities include accelerating Sonic's transition to digital pathology; providing a competitive advantage in existing dermatopathology markets; and promoting "significant synergies" with its AI partner, Franklin.ai.

Commenting on the acquisition, Sonic CEO Colin Goldschmidt said:

The acquisition of Pathology Watch is an important and enormously exciting step in Sonic's transition to digital pathology and pathology AI and offers multiple avenues for value creation.

He added that the next steps are to work with Pathology Watch to "enhance our digital pathology and AI strategy, and to provide competitive advantage for Sonic through a superior service offering to referring physicians and their patients".

The founders, management team and staff of Pathology Watch are expected to stay on with the business.

The acquisition remains subject to customary conditions. Sonic expects to close the transaction in December.

Sonic Healthcare share price snapshot

Today's fall has pushed the ASX 200 healthcare stock back into the red for 2023.

Since the opening bell on 3 January, the Sonic Healthcare share price is now down 1%.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A red heart-shaped balloon floats up above the plain white ones, indicating the best shares.
Healthcare Shares

Heart tech firm's shares surge after huge capital raise

A strategic investor has also jumped on board.

Read more »

Lab technician in lab with a tray of specimens
Healthcare Shares

Has this ASX 200 stock just turned the corner after 7% surge?

Brokers think the volatile biotech share can sustain the rally this time.

Read more »

Green stock market graph with a rising arrow symbolising a rising share price.
Opinions

3 ASX shares tipped to climb over 100% in 2026

Analysts expect steep gains this year.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Opinions

4DMedical shares crash 20% this week: Should investors cut their losses on the once-booming stock?

The shares are now down 6.61% for the year to date.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

Top broker tips 57% upside for beaten-down Telix shares

A leading broker expects a big rebound in Telix shares in 2026.

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

Here's why Anteris shares are in a trading halt today

The company is undertaking a US$300m capital raising.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Telix shares in focus as the company meets guidance

More good news from the drug developer.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

What are the healthcare stocks where RBC Capital Markets thinks you can make money?

The top buys in the sector, listed.

Read more »